

## DESCRIPTION

COMPOSITION FOR WHITENING

## TECHNICAL FIELD

The present invention relates to a novel composition, more particularly a composition for whitening (whitening agent).

## BACKGROUND OF THE INVENTION

Pigmentations such as chloasmas, freckles, sunburn, dark skin and melanoderma caused by a drug such as steroid are generated by excess deposition of melanin pigment in the skin. It is known that biosynthesis of melanin occurs in a cytoplasmic granule, melanosome, in the melanocyte via a complex pathway in which tyrosine is oxidized by tyrosinase to cause biosynthesis of dopa and dopaquinone, and the dopaquinone is converted into indolequinone or the like due to auto-oxidation by ultraviolet rays. Particularly, such pigmentations are not preferable for women from the beauty point of view.

Known preventive and therapeutic agents for pigmentations (whitening agents) include L-ascorbic acid and its derivatives (cf. JP-A-49-86554), kojic acid (cf. JP-A-53-3538), L-cysteine (cf. JP-A-59-128320), arbutin (cf. JP-A-60-56912), a bearberry (*Arctostaphylos uva-ursi*) and its extracts (cf. JP-A-6-166609), an admixture of tranexamic acid and ascorbic acid (cf. JP-A-4-243825) and the like.

However, these agents were not always advantageous in terms of their effect and the like.

## DISCLOSURE OF THE INVENTION

The present invention provides a composition for whitening (whitening agent) having more superior effect.

As a result of intensive studies, the present inventors found that superior whitening effect can be obtained when tranexamic acid or a salt thereof is jointly used with L-cysteine, a derivative thereof or a salt thereof, and thus the present invention has been completed.

That is, the present invention relates to the followings.

- (1) A composition which comprises (i) tranexamic acid or a salt thereof and (ii) L-cysteine, a derivative thereof or a salt thereof.
- (2) A composition which comprises (i) 50 to 2,500 mg of tranexamic acid or a salt thereof and (ii) 30 to 750 mg of L-cysteine, a derivative thereof or a salt thereof, in terms of administrating amounts (doses) per day.
- (3) A composition which comprises tranexamic acid and L-cysteine.
- (4) A composition which comprises 50 to 2,500 mg of tranexamic acid and 30 to 750 mg of L-cysteine, in terms of administrating amounts (doses) per day.
- (5) A composition which comprises (i) tranexamic acid or a salt thereof, (ii) L-cysteine, a derivative thereof or a salt thereof and (iii) L-ascorbic acid, a derivative thereof or a salt thereof.
- (6) A composition which comprises (i) 50 to 2,500 mg of tranexamic acid or a salt thereof, (ii) 30 to 750 mg of L-cysteine, a derivative thereof or a salt thereof and (iii) 50 to 3,000 mg of L-ascorbic acid, a derivative thereof or a salt thereof, in terms of administrating amounts (doses) per day.
- (7) A composition which comprises tranexamic acid, L-cysteine and L-ascorbic acid.

- (8) A composition which comprises 50 to 2,500 mg of tranexamic acid, 30 to 750 mg of L-cysteine and 50 to 3,000 mg of L-ascorbic acid, in terms of administrating amounts (doses) per day.
- (9) The composition according to any one of (1) to (8), which is used for whitening.
- (10) The composition according to any one of (1) to (8), which is used for preventing and/or treating pigmentations.
- (11) The composition according to any one of (1) to (10), wherein its dosage form is an oral administration preparation.
- (12) A method of whitening, which comprises administering (i) tranexamic acid or a salt thereof and (ii) L-cysteine, a derivative thereof or a salt thereof.
- (13) A method for treating pigmentations, which comprises administering (i) tranexamic acid or a salt thereof and (ii) L-cysteine, a derivative thereof or a salt thereof.
- (14) A method of whitening, which comprises administering (i) tranexamic acid or a salt thereof, (ii) L-cysteine, a derivative thereof or a salt thereof and (iii) L-ascorbic acid, a derivative thereof or a salt thereof.
- (15) A method for treating pigmentations, which comprises administering (i) tranexamic acid or a salt thereof, (ii) L-cysteine, a derivative thereof or a salt thereof and (iii) L-ascorbic acid, a derivative thereof or a salt thereof.

#### BEST MODE FOR CARRYING OUT THE INVENTION

Tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid) or a salt thereof according to the present invention is a known compound, and regarding its obtaining method, a commercially available product may be used or it may be produced based on a known method. Examples of the salt of tranexamic acid include mineral acid salts such as hydrochloride, nitrate, and sulfate; organic acid salts such as

methanesulfonate; alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and the like. According to the present invention, tranexamic acid is preferred as the tranexamic acid or a salt thereof.

The L-cysteine, a derivative thereof or a salt thereof according to the present invention is also a known compound, and as its obtaining method, a commercially available product may be used or it may be produced based on a known method. Examples of the derivatives of L-cysteine include N-acetyl-L-cysteine, L-homocysteine, L-cysteic acid, L-homocysteic acid, L-cysteine sulfinic acid, S-sulfinyl-L-cysteine, S-sulfo-L-cysteine, cystine (dimer of cysteine) and the like. In addition, examples of the salt of L-cysteine or a derivative thereof include mineral acid salts such as hydrochloride, nitrate, and sulfate; alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and the like. According to the present invention, L-cysteine is preferred as the L-cysteine, a derivative thereof or a salt thereof.

The L-ascorbic acid, a derivative thereof or a salt thereof according to the present invention is also a known compound, and regarding its obtaining method, a commercially available product may be used or it may be produced based on a known method. Examples of the salt of L-ascorbic acid or a derivative thereof include mineral acid salts such as hydrochloride, nitrate, and sulfate; alkali metal salts or alkaline earth metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and the like. Examples of the L-ascorbic acid, a derivative thereof or a salt thereof include L-ascorbic acid; L-ascorbic acid salts such as sodium L-ascorbate, magnesium L-ascorbate, potassium L-ascorbate, and calcium L-ascorbate; ascorbic acid monoalkyl or monoalkenyl esters such as L-ascorbic acid monostearate, L-ascorbic acid monopalmitate, and L-ascorbic acid monooleate; ascorbic acid dialkyl or dialkenyl esters such as L-ascorbic acid distearate, L-ascorbic acid dipalmitate, and L-ascorbic

acid dioleate; ascorbic acid trialkyl or trialkenyl esters such as L-ascorbic acid tristearate, L-ascorbic acid tripalmitate, and L-ascorbic acid trioleate; L-ascorbyl sulfates such as L-ascorbyl sulfuric acid, sodium L-ascorbyl sulfate, potassium L-ascorbyl sulfate, magnesium L-ascorbyl sulfate, and calcium L-ascorbyl sulfate; L-ascorbyl phosphates such as L-ascorbyl phosphoric acid, sodium L-ascorbyl phosphate, potassium L-ascorbyl phosphate, magnesium L-ascorbyl phosphate, and calcium L-ascorbyl phosphate; and ascorbic acid glycosides such as L-ascorbic acid glucoside. According to the present invention, L-ascorbic acid is preferred as the L-ascorbic acid, a derivative thereof or a salt thereof.

The composition for whitening (whitening agent) of the present invention is administered to a person aiming at preventing and/or treating pigmentations such as chloasmas, freckles, sunburn, dark skin and melanoderma caused by a drug such as steroid.

The composition of the present invention may be further blended with known components which show whitening effect and components that reinforce whitening effect. Examples of these components include pantothenic acid, derivatives thereof or salts thereof (pantothenic acid; pantothenate, such as sodium pantothenate and calcium pantothenate; pantetheine; pantethine; phosphopantetheine; *etc.*), hydroquinone or derivatives thereof (hydroquinone; hydroquinone glucoside such as hydroquinone- $\beta$ -D-glucose (arbutin); *etc.*), glucosamine or derivatives thereof (glucosamine; glucosamine esters such as acetylglucosamine; glucosamine ethers such as glucosamine methyl ether; *etc.*), hinokitiol or derivatives thereof (hinokitiol; hinokitiol glucoside such as hinokitiol glucoside; *etc.*), azelaic acid, derivatives thereof or salts thereof (azelaic acid; azelaic acid monoesters such as azelaic acid monoalkyl ester; azelaic acid diester such as azelaic acid dialkyl ester; *etc.*), tocopherols ( $\alpha$ -tocopherol,  $\beta$ -tocopherol,  $\gamma$ -tocopherol,  $\delta$ -tocopherol, *etc.*), ubiquinones (coenzyme Q<sub>6</sub>

(CoQ<sub>6</sub>), coenzyme Q<sub>7</sub> (CoQ<sub>7</sub>), coenzyme Q<sub>8</sub> (CoQ<sub>8</sub>), coenzyme Q<sub>9</sub> (CoQ<sub>9</sub>), coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>), *etc.*), carotenes (carotene, lutein, violaxanthin, spirilloxanthin, spheroidene, *etc.*), flavones (flavone, apigenin, luteolin, and glucosides thereof; *etc.*), isoflavone or derivatives thereof (isoflavone, isoflavone glucosides, *etc.*), flavanone or derivatives thereof (naringenin, eriodictyol, naringin, *etc.*), catechins (catechin, catechin gallate, gallic acid, *etc.*), flavonols (kaempferol, quercetin, myricetin, and glucosides thereof, *etc.*), glycyrrhizic acid, derivatives thereof or salts thereof (glycyrrhizic acid; glycyrrhizinate such as dipotassium glycyrrhizinate and monoammonium glycyrrhizinate; *etc.*), glycyrrhetic acid, derivatives thereof or salts thereof (glycyrrhetic acid; glycyrrhetic acid alkyl ester such as stearyl glycyrrhetinate; *etc.*), kojic acid, derivatives thereof or salts thereof (kojic acid; kojic acid monoalkyl esters such as kojic acid monobutylate, kojic acid monocaprate, kojic acid monopalmitate and kojic acid monostearate; kojic acid dialkyl esters such as kojic acid dibutylate, kojic acid dipalmitate, kojic acid distearate and kojic acid dioleate; *etc.*), ellagic acid, derivatives thereof or salts thereof (ellagic acid; ellagic acid ethers such as ellagic acid tetramethyl ether; acyl derivatives of ellagic acid such as ellagic acid tetraacetate and ellagic acid tetrabenzoate; *etc.*), glutathione, derivatives thereof or salts thereof (glutathione; S-acylglutathiones such as S-lactoylglutathione; N,S-diacylglutathione diesters such as N,S-dioctanoylglutathione distearyl and N,S-dipalmitoylglutathione dicetyl; *etc.*), resorcinol or derivatives thereof (resorcinol; alkylated resorcinol such as 4-n-butylresorcinol, 4-isoamylresorcinol, 4-cyclohexylresorcinol and 5-methylresorcinol; halogenated resorcinol such as 4-chlororesorcinol and 4-bromoresorcinol; *etc.*), glycogen; coix seed, hamamelis (*Hamamelis mamelodis*), saxifrage (*Saxifraga stolonifera*), *Aquilaria agallocha*, char (*Thea sinensis*), Japanese knotweed (*Polygonum cuspidatum*), Melissa (*Melisa officinalis*), thyme (*Thymus vulgaris*), *Artemisia capillaris*, yarrow (*Achillea millefolium*), hypericum (*Hypericum erectum*), St. John's

wort (*Hypericum perforatum*), peony (*Paeonia lactiflora*), peony (*Paeonia suffruticosa*), liquorice (*Glycyrrhiza glabra*), Glycyrrhiza (*Glycyrrhiza uralensis*), mulberry (*Morus bombycis*), mulberry (*Morus alba*), *Morus australis*, *Sophora flavescens*, *Artctostaphylos uva-ursi*, *Dictyopteris prolifera*, *Dictyota linearis*, *Sargassum fusiforme*, *Lomentaria catenata*, white mountain heather (*Cassiope lycopodioides*), *Rhodymenia palmata*, *Sargassum ringgoldianum coreanum* (*Sargassum ringgoldianum*), *Sargassum yezoense*, *Sargassum confusum*, *Sphaerotrichia divaricata*, sundew (*Drosera rotundifolia*), *Drosera spatulata*, lavender (*Lavandula*), coptis rhizome (*Coptis japonicus*), Job's tears (*Coix lacryma-joli*), *Epigaea asiatica*, trailing arbutus (*Epigaea repens*), passion flower (*Passiflora incarnata*), passion fruit (*Passiflora edulis*), water lemon, passion flower (*Passiflora caerulea*), *Passiflora altebilobata*, *Passiflora moluccana* or *Passiflora cochinchinensis*, *Passiflora cupiformis*, wild pansy (*Viola tricolor*), sweet violet (*Viola odorata*), violet (*Violaceae*), *Viola japonica*, *Viola yedoensis*, *Viola verecunda*, *Viola diffusa*, *Viola patrinii*, *Viola acuminata*, Nepalese violet, *Viola patrini*, *Viola collina*, *Viola sororia*, *Viola grypoceras*, *Viola philippica*, *Viola vaginata*, *Viola verecunda*, *Clematis chinensis* Osbeck, clematis (*Clematis florida*), clematis (*Clematis patens*), virgin's bower (*Clematis terniflora*), hardy rubber tree (*Eucommia ulmoides*), *Euonymus trichocarpus* Hayata, *Euonymus oxyphyllus*, asparagus (*Asparagus officinalis*), *Polygonum bistorta* or *Bistorta major*, green pea (*Pisum sativum*), *Rosa multiflora*, *Scutellaria baicalensis*, *Ononis*, blackberry or raspberry (*Rubus*), *Sophora flavescens*, *Millettia reticulata*, *Acanthopanax gracilistylus*, *Asiasarum sieboldii*, hawthorn (*Crataegus cuneata*), *Cassia nomame*, white lily, *Inula japonica*, *Morus alba*, soybean, tea, extracts of Japanese Angelica (*Angelica acutiloba*), molasses, *Ampelopsis japonica* Makino, beech, grape seeds, Frode manita, hops, *Rosa rugosa*, *Chaenomeles sinensis* or *Pseudocydonia sinensis*, *Momordica grosvenori*, Aloe (*Aloe ferox*), althea (*Althaea*), arnica (*Arnica*), Umbelliferae (*Angelica keiskei*),

*Artemisia capillaris*, nettle (*Urtica*), turmeric (*Curcuma*), *Phellodendron amurense*, German chamomile (*Matricaria chamomilla*), Japanese honeysuckle (*Lonicera japonica*), watercress (*Nasturtium officinale*), confrey (*Symphytum officinale*), sage (*Salvia*), *Lithospermum erythrorhizon*, beefsteak plant (*Perilla*), white birch (*Betula platyphylla*), pot marigold (*Calendula officinalis*), *Sambucus sieboldiana*, *Typha latifolia*, *Sapindus mukurossi*, milk-vetch (*Astragalus sinicus*), mugwort (*Artemisia*), eucalyptus (*Eucalyptus*), multiflora rose (*Rosa multiflora*), ginkgo (*Ginkgo biloba*), *Alnus*, wolfberry (*Lycium chinense*), *Micromelum minutum*, *Micromelum pubescens*, *Melothria indica*, *Mangifera indica*, *Melothria japonica*, raspberry (*Rubus idaeus*), firethorn (*Pyracantha fortuneana*) or extracts thereof; placenta extracts; and the like, although they are not limited to the above components. These components may be blended alone or as a combination of two or more thereof. Components other than the known components which show whitening effect and components that reinforce whitening effect may also be added to the composition for whitening (whitening agent) of the present invention. The blending amounts of these components are not particularly limited, so long as they do not spoil the whitening effect of the composition of the present invention.

The composition of the present invention may be orally or parenterally administered (dosed). Examples of the preparations which are orally administered (oral administration preparations) include dosage forms such as tablets, capsules, powders, fine granules, solutions, troches, and jellies. Examples of the preparations which are parenterally administered (parenteral administration preparations) include dosage forms such as extracts, hard cream preparations, spirits, suppositories, suspensions, tinctures, ointments, cataplasmas, liniments, lotions, aerosols, ophthalmic solutions, and injections, and dosage forms such as extracts, hard cream preparations, spirits, suspensions, tinctures, ointments, cataplasmas, liniments, lotions, and aerosols



are preferred as the parenteral administration preparations. In addition, it is possible to make the composition for whitening of the present invention into an embodiment of cosmetic compositions such as lotion, cream, face lotion, milky lotion, foam preparations, foundation, pack preparations, skin lotion, shampoo, rinse, and conditioner.

Pharmaceuticals can be prepared by conventionally known preparation techniques, and appropriate pharmaceutical additives can be added to the pharmaceuticals. Examples of the pharmaceutical additives include excipients, binders, disintegrants, lubricants, glidants, suspending agents, emulsifiers, stabilizers, moisture keeping (moistening) agents, preservatives, solvents, solubilizers, antiseptics, flavoring substances, sweeteners, dyes, flavors, propellants and the like, and these pharmaceutical additives may be selected and added in appropriate amounts within such a range that they do not spoil the effects of the present invention.

Regarding the blending ratio of (i) tranexamic acid or a salt thereof and (ii) L-cysteine, a derivative thereof or a salt thereof in the composition of the present invention, an appropriate blending ratio may be determined by optionally carrying out examinations, but as a weight ratio, (i) : (ii) = 1 : 0.01 to 15 is preferred, 1 : 0.1 to 1.5 is more preferred, and 1 : 0.32 is most preferred. Also, regarding the blending ratio of (i) tranexamic acid or a salt thereof, (ii) L-cysteine, a derivative thereof or a salt thereof and (iii) L-ascorbic acid, a derivative thereof or a salt thereof in the composition of the present invention, an appropriate blending ratio may be determined by optionally carrying out examinations, but as a weight ratio, (i) : (ii) : (iii) = 1 : 0.01 to 15 : 0.01 to 60 is preferred, 1 : 0.1 to 1.5 : 0.1 to 6 is more preferred, and 1 : 0.32 : 0.4 is most preferred.

An appropriate administrating amount (dose) of the composition for whitening of the present invention may be determined by carrying out optional examinations in terms of sex, age and symptoms of each user, administrating (dosing)

method, administrating (dosing) frequency, administrating (dosing) time and the like. For example, in the case of an internal use, it is preferable to formulate in such a manner that 50 to 2,500 mg per day of tranexamic acid or a salt thereof is administered (dosed), and it is more preferable to formulate in such a manner that from 400 to 2,000 mg is administered (dosed). Also, it is preferable to formulate L-cysteine, a derivative thereof or a salt thereof in such a manner that 30 to 750 mg per day of the compound is administered (dosed), and it is more preferable to formulate it in such a manner that 150 to 480 mg of the compound is administered (dosed). In addition, it is preferable to formulate L-ascorbic acid, a derivative thereof or a salt thereof in such a manner that 50 to 3,000 mg per day of the compound is administered (dosed), and it is more preferable to formulate it in such a manner that 300 to 2,000 mg of the compound is administered (dosed).

The composition of the present invention may be administered (dosed) by making it into a single pharmaceutical preparation containing all of the components concerned in the present invention, or each of the components concerned in the present invention may be made into separate pharmaceutical preparations to obtain a kit preparation in which simultaneous or sequential administration (dose) of these preparations is possible.

Although the present invention is described below in detail based on examples, the present invention should not be limited thereto.

## 1. Pigmentation inhibitory effect

### 1.1 Test methods

#### 1.1.1 Examination of ultraviolet ray (UVB) irradiation time

Ultraviolet ray (UVB) irradiation time was examined using two female 6-week-old Kw1:A-1 brown guinea pigs (SPF). That is, one of the guinea pigs was fixed

on the abdominal position, and three 2 cm × 2 cm square ultraviolet ray irradiating sites were arranged in bilateral symmetry with the dorsal midline between, thus six sites in total. By shading the body except for the ultraviolet ray irradiating sites, an ultraviolet ray (UVB) was irradiated from a distance of 40 cm using five SE lamps (wavelength 250 to 350 nm, FL20S-E, manufactured by TOSHIBA). By setting the irradiation time to 4, 6, 8, 10, 12 or 14 minutes, skin reaction of each irradiating site (the presence and degree of erythema) was observed on the next day.

Next, by further setting the irradiation times at intervals of 15 seconds between the minimum time when the skin reaction was observed and the maximum time when the skin reaction was not observed, eight irradiating sites were arranged on the other guinea pig in the same manner as in the former case and then the skin reaction was observed, thus setting the ultraviolet ray (UVB) irradiation time in the test to 11 minutes and 30 seconds and 11 minutes and 45 seconds.

#### 1.1.2 Test samples

Test samples were dissolved in distilled water for injection to the following concentrations.

Sample (1): control (no addition)

Sample (2): tranexamic acid 37.5 mg/ml

Sample (3): L-cysteine 12 mg/ml

Sample (4): ascorbic acid 15 mg/ml

Sample (5): tranexamic acid 37.5 mg/ml + ascorbic acid 15 mg/ml

Sample (6): tranexamic acid 37.5 mg/ml + L-cysteine 12 mg/ml

Sample (7): L-cysteine 12 mg/ml + ascorbic acid 15 mg/ml

Sample (8): tranexamic acid 37.5 mg/ml + L-cysteine 12 mg/ml + ascorbic acid 15 mg/ml

#### 1.1.3 Ultraviolet ray irradiation

Examination was made by using five female 7-week-old Kwl:A-1 brown guinea pigs (SPF) in one group. That is, each of the guinea pigs was fixed on the abdominal position using a fixation plate on the respective ultraviolet ray irradiating days (on the day of the commencement of sample administration and on the 2nd and 4th days thereafter). One 2 cm × 2 cm square arranged on the left or right side with the guinea pig dorsal midline between was used as the ultraviolet ray irradiating site, and the body was shaded except for the ultraviolet ray irradiating site. Two guinea pigs in one group were irradiated with an ultraviolet ray (UVB) for 11 minutes and 30 seconds, and three guinea pigs in one group, from a distance of 40 cm using five SE lamps (wavelength 250 to 350 nm, FL20S-E, manufactured by TOSHIBA). During the testing period (14 days), each test sample was orally administered twice a day. Each sample solution was administered at a dose of 10 ml/kg. In this case, the administration was carried out after the ultraviolet ray irradiation on each ultraviolet ray irradiation day, or after the judgment on each pigmentation judging day.

#### 1.1.4 Judgment of pigmentation

Before the irradiation on the day of the commencement of test sample administration and on the final day of the test, a  $\Delta L$  value (L value on the observation day - L value before irradiation) was calculated by measuring L value (lightness) of the irradiated site using a color-difference meter (CR-300, manufactured by MINOLTA CAMERA). The results are shown in Table 1 (larger  $\Delta L$  values show higher effect).

Table 1

	Day of commencement	Final day of the test	
	L value	L value	$\Delta L$ value
Sample (1)	$61.79 \pm 1.33$	$54.68 \pm 1.20$	$-7.10 \pm 1.45$
Sample (2)	$62.06 \pm 0.83$	$58.30 \pm 1.20$	$-3.76 \pm 1.78^*$
Sample (3)	$62.83 \pm 1.55$	$59.52 \pm 3.10$	$-3.32 \pm 1.70^{**}$
Sample (4)	$62.11 \pm 0.81$	$57.35 \pm 1.56$	$-4.76 \pm 1.62^*$
Sample (5)	$62.07 \pm 0.96$	$58.62 \pm 2.93$	$-3.45 \pm 2.28^*$
Sample (6)	$62.24 \pm 0.62$	$59.54 \pm 1.26$	$-2.70 \pm 1.56^{**}$
Sample (7)	$62.68 \pm 1.03$	$56.18 \pm 2.06$	$-6.50 \pm 1.65$
Sample (8)	$62.98 \pm 1.75$	$60.79 \pm 2.45$	$-2.20 \pm 1.00^{**}$

\*:  $p < 0.05$ , \*\*:  $p < 0.01$  vs sample (1)

## 1.2 Results

As is evident from Table 1, the samples (6) and (8) concerned in the present invention showed excellent pigmentation inhibitory effect. That is, in comparison with the tranexamic acid-single administered group (sample (2) in the table) and the L-cysteine-single administered group (sample (3) in the table), the tranexamic acid- and L-cysteine-administered group (sample (6) in the table) showed excellent pigmentation inhibitory effect.

In addition, the L-cysteine- and ascorbic acid-administered group (sample (7) in the table) from which a certain degree of pigmentation inhibitory effect was expected showed no effect contrary to the expectation but rather showed an effect to accelerate pigmentation. This is evident when compared with the results of the L-cysteine-single administered group (sample (3) in the table) and ascorbic acid-single administered group (sample (4) in the table).

On the other hand, the group in which L-cysteine, ascorbic acid and tranexamic acid were administered (sample (8) in the table) not only turned the pigmentation acceleration of the sample (7)-administered group to pigmentation inhibition but also showed markedly excellent pigmentation inhibitory effect.

## 2. Formulation examples

### 2.1 Tablets

Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).

Tranexamic acid	1,500 mg
L-Cysteine	240 mg
Microcrystalline cellulose	100 mg
Corn starch	40 mg
Low substituted hydroxypropylcellulose	50 mg
Hydroxypropylcellulose	30 mg
Magnesium stearate	20 mg
Hydroxypropylmethylcellulose 2910	60 mg
Macrogol 6000	12 mg
Talc	10 mg
Titanium oxide	18 mg

### 2.2 Tablets

Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).

Tranexamic acid	750 mg
L-Cysteine	240 mg

L-Ascorbic acid	300 mg
Microcrystalline cellulose	200 mg
Corn starch	100 mg
Low substituted hydroxypropylcellulose	90 mg
Hydroxypropylcellulose	30 mg
Magnesium stearate	25 mg
Hydroxypropylmethylcellulose 2910	80 mg
Macrogol 6000	16 mg
Talc	14 mg
Titanium oxide	24 mg

### 2.3 Tablets

Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).

Tranexamic acid	750 mg
L-Cysteine	160 mg
L-Ascorbic acid	300 mg
$\alpha$ -Tocopherol	300 mg
Microcrystalline cellulose	170 mg
Corn starch	200 mg
Low substituted hydroxypropylcellulose	70 mg
Hydroxypropylcellulose	30 mg
Magnesium stearate	20 mg
Hydroxypropylmethylcellulose 2910	60 mg
Macrogol 6000	12 mg
Talc	10 mg

Titanium oxide	18 mg
----------------	-------

## 2.4 Tablets

Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).

Tranexamic acid	1,000 mg
L-Cysteine	480 mg
L-Ascorbic acid	600 mg
Pyridoxine hydrochloride	100 mg
Riboflavin	30 mg
Microcrystalline cellulose	200 mg
Corn starch	950 mg
Hydroxypropylcellulose	50 mg
Magnesium stearate	25 mg
Hydroxypropylmethylcellulose 2910	75 mg
Macrogol 6000	15 mg
Talc	11.5 mg
Titanium oxide	22.5 mg

## 2.5 Solutions

Solutions were produced in the usual way based on the following composition (100 ml as daily dose).

Tranexamic acid	1,000 mg
L-Cysteine	240 mg
<i>Keishi-bukuryo-gan</i> extract	3,750 mg
Sorbitol	3,000 mg



Citric acid	100 mg
Sodium citrate	30 mg
Perfume	proper amount
Purified water	100 ml

## 2.6 Tablets

Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).

Tranexamic acid	1,000 mg
L-Cysteine	240 mg
Chamomile ( <i>Matricaria chamomilla</i> )	600 mg
Bearberry ( <i>Arctostaphylos uva-ursi</i> )	300 mg
Microcrystalline cellulose	200 mg
Corn starch	165 mg
Hydroxypropylcellulose	50 mg
Magnesium stearate	25 mg
Hydroxypropylmethylcellulose 2910	75 mg
Macrogol 6000	15 mg
Talc	11.5 mg
Titanium oxide	22.5 mg

## 2.7 Tablets

Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).

Tranexamic acid	1,000 mg
L-Cysteine	240 mg

Ceramide	20 mg
Microcrystalline cellulose	150 mg
Corn starch	145 mg
Hydroxypropylcellulose	25 mg
Magnesium stearate	10 mg
Hydroxypropylmethylcellulose 2910	42 mg
Macrogol 6000	7 mg
Talc	168 mg
Titanium oxide	7 mg
Sucrose	660 mg
Acacia	17 mg
Precipitated calcium carbonate	150 mg

## 2.8 Tablets

Tablets were produced in the usual way based on the following composition (6 tablets as daily dose).

Tranexamic acid	1,000 mg
L-Cysteine	480 mg
Flavangenol	30 mg
Collagen	1,000 mg
Microcrystalline cellulose	203 mg
Corn starch	40 mg
Low substitution degree hydroxypropylcellulose	70 mg
Hydroxypropylcellulose	50 mg
Magnesium stearate	27 mg
Hydroxypropylmethylcellulose 2910	80 mg

Macrogol 6000	16 mg
Talc	14 mg
Titanium oxide	24 mg

## 2.9 Vanishing cream

A vanishing cream (100 g) was produced in the usual way based on the following composition.

(A)	Polysorbate 60	1 g
	Polyoxyethylene sorbitol tetraoleate (60E.O.)	0.5 g
	Glyceryl monostearate (oleophilic type)	1.0 g
	Cetyl palmitate	4.0 g
	Paraffin wax (135°F)	3.0 g
	Stearic acid	8.0 g
	Behenyl alcohol	2.0 g
	Cetyl isooctanoate	6.0 g
	Butylparaben	0.1 g
(B)	Methylparaben	0.1 g
	2% Sodium hydroxide aqueous solution	4.0 g
	1,3-Butylene glycol	7.0 g
	Tranexamic acid	1.0 g
	L-Cysteine	1.0 g
	Purified water	balance

## 2.10 Milky lotion

A milky lotion (100 g) was produced in the usual way based on the following composition.

(A)	Polysorbate 60	1 g
	Polyoxyethylene sorbitol tetraoleate (60E.O.)	0.5 g
	Glyceryl monostearate (oleophilic type)	1.0 g
	Stearic acid	0.5 g
	Behenyl alcohol	0.5 g
	Liquid paraffin	4.0 g
	Glyceryl tri-2-ethylhexanoate	4.0 g
	Cetyl isooctanoate	2.0 g
	Butylparaben	0.1 g
(B)	Methylparaben	0.1 g
	Carboxyvinyl polymer (1% aqueous solution)	5.0 g
	1,3-Butylene glycol	5.0 g
	Tranexamic acid	1.0 g
	L-Cysteine	1.0 g
	Magnesium L-ascorbylphosphate	1.0 g
	With purified water to	90.0 g
(C)	1% Sodium hydroxide aqueous solution	2.5 g
	Purified water	7.5 g
(D)	Perfume	proper amount

## 2.11 Lotion

A lotion (100 g) was produced in the usual way based on the following composition.

(A)	POE hydrogenated castor oil 60	1.0 g
	Perfume	proper amount
	Ethanol	15.0 g

	Methylparaben	0.1 g
(B)	Citric acid	0.1 g
	Sodium citrate	0.3 g
	1,3-Butylene glycol	4.0 g
	Tranexamic acid	1.0 g
	L-Cysteine	1.0 g
	Magnesium L-ascorbylphosphate	1.0 g
	Purified water	balance

#### Industrial Applicability

The composition of the present invention showed excellent melanin pigment deposition inhibitory effect. Accordingly, the composition of the present invention is useful as a composition used for whitening (whitening agent) and also as a composition for the prevention and/or treatment of pigmentations such as chloasmas, freckles, sunburn, dark skin and melanoderma caused by a drug such as steroid.